Business Context and Reporting Period
This Form 8-K Current Report is filed by Aquestive Therapeutics, Inc. for the reporting period of July 27, 2018. The filing documents the completion of the Company's initial public offering (IPO) and the concurrent effectiveness of amendments to its governing corporate documents.
Key Financial Metrics
The filing details the capital raise from the IPO but does not provide historical revenue, profit, cash flow, or margin data.
- Shares Issued: 4,500,000 shares of common stock.
- Offering Price: $15.00 per share (before underwriting discount).
- Gross Proceeds: $67,500,000 (calculated as 4,500,000 shares x $15.00).
- Underwriters: Syndicate led by BMO Capital Markets Corp. and RBC Capital Markets, LLC.
- Debt and Liquidity: The filing text does not provide specific values for existing debt or liquidity positions outside of the new equity proceeds.
Material Changes
The primary material change reported is the transition to a publicly traded company status via the IPO. Additionally, the Company's Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws became effective on July 27, 2018, replacing previous governance structures.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors. It strictly reports the completion of the offering and the legal effectiveness of the new Charter and Bylaws. No unusual items or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses, as the $15.00 price is pre-discount.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) for specific shareholder rights and governance provisions.
- Consult the Company's Registration Statement on Form S-1 (File No. 333-225924) for detailed financial statements, risk factors, and use of proceeds not included in this 8-K.
- Confirm the lock-up period and trading restrictions for existing shareholders and underwriters.